Bachem Holding AG (SWX:BANB)
Switzerland
· Delayed Price · Currency is CHF | Market Cap | 5.14B |
| Revenue (ttm) | 695.07M |
| Net Income (ttm) | 148.79M |
| Shares Out | 74.94M |
| EPS (ttm) | 1.98 |
| PE Ratio | 34.59 |
| Forward PE | 28.27 |
| Dividend | 0.90 (1.31%) |
| Ex-Dividend Date | May 4, 2026 |
| Volume | 109,637 |
| Average Volume | 136,305 |
| Open | 68.10 |
| Previous Close | 68.65 |
| Day's Range | 67.30 - 69.40 |
| 52-Week Range | 48.20 - 76.00 |
| Beta | 0.79 |
| RSI | 54.53 |
| Earnings Date | Jul 30, 2026 |
About Bachem Holding AG
Bachem Holding AG, together with its subsidiaries, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. It engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). The company also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing practice production, research grade production, an... [Read more]
Financial Performance
In 2025, Bachem Holding AG's revenue was 695.07 million, an increase of 14.84% compared to the previous year's 605.26 million. Earnings were 148.79 million, an increase of 23.74%.
Financial StatementsNews
Bachem Holding AG Earnings Call Transcript: H2 2025
Sales grew 14.8% to CHF 695.1 million in 2025, with EBITDA margin at 30.9%. 2026 guidance targets 35%-45% sales growth and low 30s% EBITDA margin, driven by Building K ramp-up and strong demand for complex peptides and oligonucleotides.
Bachem Holding AG Earnings Call Transcript: H1 2025
Sales grew 30.2% to CHF 313M with EBITDA up 64% and margin at 29.1%. CapEx and workforce expanded to support future growth, and guidance was raised for 2024 with strong demand in peptides and oligonucleotides.
Bachem Holding AG Earnings Call Transcript: H2 2024
Revenue grew to CHF 605.3 million in 2024, with all segments expanding and EBITDA margin rising to 29.1%. CapEx surged, driven by major projects like Building K, and 2025 guidance targets 10–15% sales growth and high-20s EBITDA margin.
Bachem Holding AG Transcript: CMD 2024
Strong market demand for peptides and oligonucleotides is driving major capacity expansion, with Building K and Sisslerfeld set to support ambitious growth targets. Innovation in manufacturing and technology, robust customer contracts, and a clear financial strategy underpin the goal of reaching CHF 1 billion in revenue by 2026.
Bachem Holding AG Earnings Call Transcript: H1 2024
H1 2024 saw flat sales and a 5.6% EBITDA increase, with strong CMC development growth and major investments in capacity. Guidance for 2024 and 2026 is unchanged, with Building K ramp-up expected in H1 2025 and continued focus on innovation and operational excellence.<doc